The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO 2021 | Unanswered questions in CAR-T therapies
Jennifer Brudno, MD, National Cancer Institute, Bethesda, MD, explores unanswered questions regarding chimeric antigen receptor (CAR) T-cell therapies in hematologic malignancies. Commercially available CAR T-cell therapies such as idecabtagene vicleucel and axicabtagene ciloleucel were tested in pre-treated patients in clinical trials, opening up the possibility of using CAR T-cell therapy in earlier lines of treatment. Dr Brudno suggests that administering CAR T-cell therapies earlier may increase efficacy due to patients being exposed less to prior chemotherapy and consequently having a more robust immune system. This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.
